Dawn McCollough

Part of Wesana Health Holdings, Inc., WeSana Health, Inc. engages in the development and delivery of psychedelic and naturally-sourced therapies. The company is based in Homer Glen, IL. The company was founded by Daniel Carcillo, Chad Bronstein. Daniel Carcillo has been the CEO since incorporation. WeSana Health was acquired by Debut Diamonds, Inc. on April 28, 2021.

Part of Multidisciplinary Association for Psychedelic Studies, Lykos Therapeutics, Inc. is a public benefit corporation that focuses on developing and commercializing prescription psychedelics to provide better treatments for people with mental health conditions. The private company is based in San Jose, CA. Lykos Therapeutics aims to catalyze healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics, prioritizing public benefit above profit. The company was founded in 2014, and the CEO is Amy Emerson.

Part of Wesana Health Holdings, Inc., WeSana Health, Inc. engages in the development and delivery of psychedelic and naturally-sourced therapies. The company is based in Homer Glen, IL. The company was founded by Daniel Carcillo, Chad Bronstein. Daniel Carcillo has been the CEO since incorporation. WeSana Health was acquired by Debut Diamonds, Inc. on April 28, 2021.

Part of Wesana Health Holdings, Inc., WeSana Health, Inc. engages in the development and delivery of psychedelic and naturally-sourced therapies. The company is based in Homer Glen, IL. The company was founded by Daniel Carcillo, Chad Bronstein. Daniel Carcillo has been the CEO since incorporation. WeSana Health was acquired by Debut Diamonds, Inc. on April 28, 2021.

Part of Multidisciplinary Association for Psychedelic Studies, Lykos Therapeutics, Inc. is a public benefit corporation that focuses on developing and commercializing prescription psychedelics to provide better treatments for people with mental health conditions. The private company is based in San Jose, CA. Lykos Therapeutics aims to catalyze healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics, prioritizing public benefit above profit. The company was founded in 2014, and the CEO is Amy Emerson.